Convertible Preferred Stock and Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended	5 Months Ended	6 Months Ended	11 Months Ended
	Sep. 30, 2024	Aug. 31, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Dec. 31, 2024	Nov. 30, 2024	Sep. 13, 2024
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Gross proceeds (in Dollars)					$ 2,931
Issuance costs (in Dollars)					$ 1,589
Common stock, shares authorized				545,000,000		545,000,000	545,000,000
Common stock, shares issued				37,450,745		37,450,745	37,440,510
Common stock, shares outstanding				37,450,745		37,450,745	37,440,510
Pre-Funded Warrants [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Warrants outstanding		5,522,207		6,202,207		6,202,207	6,202,207
Purchase price per share (in Dollars per share)		$ 9.7
Exercise price per warrant (in Dollars per share)		$ 0.01
Number of shares issued	680,000
Purchase price per share (in Dollars per share)	$ 22.999
Expiration date
Employee Warrants [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Warrants outstanding				3,054,358		3,054,358	3,054,358
Exercise price per warrant (in Dollars per share)							$ 7.8
Employee warrants issued							3,054,358
Vesting period							4 years
Paruka Warrant [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Exercise price per warrant (in Dollars per share)							$ 19.39
Warrant purchase							596,930
Term of warrant							10 years
Common Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Warrants exercisable	680,000	5,522,207
Common stock, shares authorized				545,000,000		545,000,000
Common stock, shares issued				37,450,745		37,450,745
Common stock, shares outstanding				37,450,745		37,450,745
Restricted Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Common stock, shares issued				2,207,553		2,207,553
Common stock, shares outstanding				2,207,553		2,207,553
Series A Preferred Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Converted shares								2,439,000
Preferred stock, shares outstanding
Series A Preferred Stock [Member] \| Fairmount [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Gross proceeds (in Dollars)			$ 3,000
Series B Preferred Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Converted shares		137,138
Preferred stock, shares outstanding				137,138		137,138
Conversion ratio				83.3332:1
Private Placement [Member] \| Common Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Exercise price per warrant (in Dollars per share)	$ 0.001
Pre-Merger Oruka [Member] \| Series A Preferred Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Issuance costs (in Dollars)			$ 100
Pre-Merger Oruka [Member] \| Series A Preferred Stock [Member] \| Fairmount [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Purchase price per share (in Dollars per share)			$ 0.15
Number of shares issued			20,000,000
PIPE Financing [Member] \| Common Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Purchase price per share (in Dollars per share)									$ 23
PIPE Financing [Member] \| Series A Preferred Stock [Member]
Convertible Preferred Stock and Stockholders’ Equity [Line Items]
Number of shares issued	2,439
Purchase price per share (in Dollars per share)	$ 23,000
Converted shares								2,439

Oruka Therapeutics, Inc. 10-Q